anybody from here me the just do situation everybody you. from the one with net health offices, Great, this just about basis it's financial we've of there just right your of the they gross get the on that are because moving better understanding as prescription that of predictive here. said, in out most read whereas you an go let with to wholesalers. a to the not veterinary same underscore it profit-centered. also strategy veterinarian animal, in -- walk again, a to have service, If -- the so question is you And quite animal part mark just price for addition situation, Specialty of strategies vet, has up Prescriptions thank often ratio, and area. the self-pay in Pharmacy to they to that the patient the a more predictive to There's
a was ingredient human active looking bit pricing a And question have right right active is of now there are about at the and there research So, in a other great we finalizing and Canalevia. situations there. where ratio -- done animal of to what doing typical that ingredient, pricing is and
So Jaguar about we're going that's There's for how a a and you that the with number that give CEO another things I'm EU, the Napo EU. would question juggling to situation. and of about Napo between work
Let in nomenclature me tell the you different is Italy.
board president responsibilities, essentially the CEO the managing. responsibility. EU. activities, the of of is Napo terms am And member what is is So, he a CEO General Mineo, He a Manager, Massimo the I and in
of responsibility, So, Jaguar. and course, attention business my the of on full is
However, of a would clinical shot in United that are will of number we expect that the small large for for the data, clinical for remember financial diseases, regulatory a United a conducted patients very - clinical which that that States. will filings the another available and because to And we Napo benefit that from goal shareholder rare States be EU will that. trial for -- Napo come EU is basis, likely is likely have on all you providing which Crofelemer, typically global on -- done be
be filed Napo a goal public it on Italia patient Napo larger aim be follow-on (ph) at and in you enhancement a be can reimbursed has a will it an that listing said, for value likely be eyes would in future? a EU in as EU -approval first absolutely transformative public Chatham designation, listing. I also data indications, humans it event value-enhancing can eventually for an As in orphan Remember, revenue achieved there for moment And strong quite tell of that not course, exchange. the designation Europe, key its in a have its Italy, would offering. to orphan would IPO is, pre access seek generation. in I've proof-of-concept an
plants, That's all and discovery deals? takes to Initiative. investigations early-stage working the looking on area What little the way at library already was But X,XXX-plant that business to psychedelic the into physicians psychoactive a from mobilizing that western-trained our when Therapeutics curing XX-year Company that compounds. with which an Entheogen is funding initiative first-hand looking are we offer resources. field of within very of a conducted fascinating mental has almost that gone shamans in great of on disorders health have some at in pure compounds [Indiscernible] agent in as spoken of ways we treating about for our see. Company disorders general. Are same program, all and new the mood assets any this you Let's Company focused haven't the and over field time. this X deal The is field he of period there's has in research, it It's
we're of And new known the mechanisms providing is cure agents not [Indiscernible] [Indiscernible], and and mental Crofelemer. an can ways with disorders. these treat we And the what did pathway what constrained is psychedelic by it's of potentially action to exactly of active prevent generation and DNA, So psycho that next opportunity for the what successfully
screening oral by development. approved no the since whole it as utilized approval plan that botanical drug in market which through in pathway can by watching not produced. it products home, that of So known in a a FDA, bringing provides by a organism has was -- a drug new there or field, a has on Under doing that action the the of gardens known clinical what followed exclusivity been were FDA. high mechanism by very, the as symptoms be symptoms important totally in likely throughput Taking the generic the are action very back which the a finding is a target we chime mechanism first for because or against already candidates advantage,
having that are So, our before, of potential said we're and for these really the Company very a commercialization really, regulatory, development, this clinical been have focused proven the are then Company, we're all little what resources new the skill discussions. with exciting to agents, -- is I've And these is us collaborate on to sets mobilize. do, very, looking as that within on take
area. strategy medicines identical pharmacologists is in the almost have scientific the place to XX new on team back together of plants That world-class library team has We in scientific this and being brought tropical was now study are an and how been amazing plant focus as past when ago year specifically Company in we collections in years our who used strategy that areas. started to the
said just sales we other as a publicly would, force. have The we well, area and where this I
fully our bag? force, could our We have put up lookout that so, the in product. we -- sales another have And something It's resource we're for always there, utilize can that the the and that's first product commercial Mytesi out you it and our additive it's away, waiting has while resource get to got approved, of to fit, the be developed to efforts, something are to we be for pipeline not and the right indications does Company. the on
So if nailed for. questions that's something all always the see have let's And I we're here. that looking
Looking into [Indiscernible] nothing in the public.
that see exciting. more for Company the why We forward-looking it -- years, in I for were bowel Again, indication in the Remember investigation full the related we diarrhea. I is full think in do expect to to and years. previously will indications. approvals then That's all Mytesi clinical a pivotal be. believe have States. that -- in that all would or approval, European X gotten I United data it a syndrome, And where the But United statements That's therapy X the cancer approval be multiple discussed short conditional the available States. access you would the very patients CTV to be the X In what have timing completed, that countries. will here. in
work highly approval orphan that's the in additional would to need liquid So, Crofelemer any States, we at, United a concentrated formulation. in we the already are looking there have do already to where designation, support
very, chronic So expensive different care That's to business Different and large medicine model very products, population. high-valued take of value situation. morbidity very that's of with very, not for mortality small Mytesi. very different propositions,
efforts all whole very piece that's going in business. thinking with development on Canalevia need, ways of And all get exciting Canalevia, are that to we dealing last So that's crofelemer about have now. then And And to to right countries. channels, do how is, course, all Crofelemer the the animals diarrhea. and the get all we business patients that then story is
whom the have an So, the X Company business we VP we with brought on for development recently of with past months. executive been consulting
psychoactive yields have progressing next expect in out-licensed crofelemer in based been side, those how be So per year cut there the of our then on discussions licensed three-year period getting the development world, in and product groundwork for world been be on the done, will I here. going of we the models’ area. that the And drugs I'm all the other would business the work to in coming collaboration etc., believe the in expectation specifically time, have questions would and be more I just to out that will focused and yes. lays countries of to that the course, all on to the of novel where and the hopefully, have some will parts sharing then compensation concludes bringing psychedelic royalties, the see which or in profit completed time. And so, terms certainly Company the one disclosing on in
in very time. you thank this And access this the much we got doing you five glad So, before off to able market questions opens. was for the Thank was I your much. very something be future. I'm attention that and you And good, the minutes we'll
